- Home
- NRIX vs KALV Comparison
NRIX vs KALV Comparison
Compare NRIX & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- KALV
- Stock Information
- Founded
- NRIX 2009
- KALV N/A
- Country
- NRIX United States
- KALV United States
- Employees
- NRIX N/A
- KALV N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- KALV Biotechnology: Pharmaceutical Preparations
- Sector
- NRIX Health Care
- KALV Health Care
- Exchange
- NRIX Nasdaq
- KALV Nasdaq
- Market Cap
- NRIX 728.6M
- KALV 637.9M
- IPO Year
- NRIX 2020
- KALV N/A
- Fundamental
- Price
- NRIX $9.91
- KALV $15.82
- Analyst Decision
- NRIX Strong Buy
- KALV Strong Buy
- Analyst Count
- NRIX 15
- KALV 9
- Target Price
- NRIX $29.13
- KALV $26.29
- AVG Volume (30 Days)
- NRIX 733.8K
- KALV 734.1K
- Earning Date
- NRIX 10-10-2025
- KALV 09-09-2025
- Dividend Yield
- NRIX N/A
- KALV N/A
- EPS Growth
- NRIX N/A
- KALV N/A
- EPS
- NRIX N/A
- KALV N/A
- Revenue
- NRIX $88,381,000.00
- KALV N/A
- Revenue This Year
- NRIX $74.59
- KALV N/A
- Revenue Next Year
- NRIX N/A
- KALV $221.95
- P/E Ratio
- NRIX N/A
- KALV N/A
- Revenue Growth
- NRIX 41.86
- KALV N/A
- 52 Week Low
- NRIX $8.18
- KALV $7.30
- 52 Week High
- NRIX $29.56
- KALV $16.32
- Technical
- Relative Strength Index (RSI)
- NRIX 47.82
- KALV 71.16
- Support Level
- NRIX $8.97
- KALV $13.72
- Resistance Level
- NRIX $9.68
- KALV $13.96
- Average True Range (ATR)
- NRIX 0.55
- KALV 0.69
- MACD
- NRIX 0.04
- KALV 0.31
- Stochastic Oscillator
- NRIX 55.13
- KALV 99.15
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.